Lynch Syndrome: From Carcinogenesis to Prevention Interventions

Area of Science:

• Genetics and Oncology
• Inherited Cancer Syndromes
• DNA Mismatch Repair

Background:

• Lynch syndrome (LS) is the most common inherited cancer predisposition.
• It significantly elevates the risk of gastrointestinal and genitourinary cancers.
• LS arises from germline pathogenic variants in DNA mismatch repair genes.

Purpose of the Study:

• To review the clinical, biologic, genetic, and morphological features of Lynch syndrome.
• To update on current screening, surveillance, and risk-reducing strategies for LS patients.
• To explore emerging preventive strategies, including pharmacological and immunological approaches.

Main Methods:

• Literature review of Lynch syndrome features and carcinogenesis models.
• Analysis of current surveillance and risk-reducing guidelines.
• Evaluation of pharmacological (aspirin) and immunological (immunocheckpoint inhibitors, vaccines) interventions.

Main Results:

• Lynch syndrome necessitates tailored surveillance and risk-reduction based on specific mutations.
• Aspirin remains a studied pharmacological intervention, though findings are conflicting.
• Novel immunotherapies show promise in both treatment and prevention settings.

Conclusions:

• Comprehensive understanding of LS features is crucial for effective management.
• Current guidelines emphasize surveillance and risk-reducing procedures.
• Emerging immunotherapies represent a promising frontier for LS cancer prevention.